Cancer-specific loss of β-defensin 1 in renal and prostatic carcinomas
Cancer-specific loss of β-defensin 1 in renal and prostatic carcinomas
复制标题
DOI：
10.1097/01.lab.0000063929.61760.f6
复制
发表时间：
2003-04-01
影响因子：
5
通讯作者：
Petros, JA
中科院分区：
文献类型：
--
作者：
Donald, CD;Sun, CQ;Petros, JA
在之前一项针对肾上皮肿瘤的大规模基因表达谱研究中，发现人β-防御素-1 (DEFB1) 在传统透明细胞（肾）癌中显着下调。我们现在已经完成了该基因的扩展表达分析。我们对肾细胞癌和前列腺癌的临床标本中的 DEFB1 蛋白进行了免疫组织化学分析。在前列腺癌的一个子集中，我们进行了激光捕获显微切割和 RT-PCR，以将 mRNA 水平与蛋白质水平相关联。总体而言，82% 的前列腺癌表现出蛋白质表达完全丧失或仅表达极少，而邻近的良性上皮在所有情况下都保留表达。同样，90% 的肾细胞癌表现出 DEFB1 蛋白的癌症特异性缺失。在前列腺癌子集分析中，mRNA 水平与蛋白质水平相关。因此，我们在前列腺癌和肾癌的大样本中证明了 DEFB1 的癌症特异性下调，并验证了先前前列腺癌和肾肿瘤的癌症基因谱研究的关键发现之一。
In a previous large-scale gene expression profiling study of renal epithelial neoplasms, human beta-defensin-1 (DEFB1) was found to be significantly down-regulated in conventional clear cell (renal) carcinoma. We have now completed an expanded expression analysis of this gene. We performed immunohistochemical analysis for the DEFB1 protein in clinical specimens of both renal cell carcinoma and prostate cancer. In a subset of prostate cancers, we performed laser capture microdissection and RT-PCR to correlate mRNA levels with protein levels. Overall, 82% of prostate cancers exhibit either complete loss of protein expression or only minimal expression, whereas the adjacent benign epithelium retained expression in all cases. Similarly, 90% of renal cell carcinomas show cancer-specific loss of DEFB1 protein. In the prostate cancer subset analysis, mRNA levels correlate with protein levels. We have thus demonstrated the cancer-specific down-regulation of DEFB1 in a large sample of prostatic and renal carcinomas and validated one of the key findings of previous cancer gene profiling studies of prostatic and renal neoplasia.